Welcome to OncologyPRO, the home of Esmo’s educational and scientific resources.

The BNT162b2 mRNA vaccine has a similar profile of short-term side effects for cancer patients undergoing immune checkpoint inhibitor therapy and healthy individuals

The RATIONALE 307 results suggest use of tislelizumab alongside chemotherapy can prolong progression-free survival for treatment-naïve, advanced squamous non-small-cell lung cancer

Phase III trial findings indicate a survival advantage for advanced biliary tract patients who receive second-line FOLFOX chemotherapy alongside active symptom control 

Chronic immune-related adverse events associated with immune checkpoint inhibitor therapy may be more common than previously thought among advanced melanoma patients 

A novel inhibitor of the mutated KRASG12C protein has shown initial positive findings in patients with advanced non-small-cell lung cancer

Advanced gastro-oesophageal cancer patients may derive a survival benefit from the addition of the novel antibody agent zolbetuximab to epirubicin, oxaliplatin and capecitabine

Breast cancer patients with distant lymph node metastases show survival outcomes similar to women with locoregional disease

Phase III trial findings indicate that relapsed platinum-sensitive ovarian cancer patients can benefit from secondary cytoreduction before chemotherapy